Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31055720 | 0.89 | GAA (0.39) | NLRP3GAA | |
| SCHEMBL31055695 | 0.89 | NLRP3 (0.48) | NLRP3GAA | |
| SCHEMBL26975378 | 0.88 | GAA (0.56) | NLRP3GAA | |
| SCHEMBL26975351 | 0.86 | NLRP3 (0.52) | NLRP3 | |
| SCHEMBL26975363 | 0.85 | ACHE (0.44) | NLRP3GAA | |
| SCHEMBL19259633 | 0.85 | NLRP3 (0.45) | NLRP3GAA | |
| SCHEMBL26975352 | 0.84 | NLRP3 (0.43) | NLRP3GAA | |
| SCHEMBL26975370 | 0.84 | NLRP3 (0.43) | NLRP3GAA | |
| SCHEMBL26975375 | 0.84 | NLRP3 (0.43) | NLRP3GAA | |
| SCHEMBL26975354 | 0.83 | NLRP3 (0.42) | NLRP3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858922-B2 | Sulfonylureas and related compounds and use of same | NLRP3, NOD1, PYCARD | NLRP3 1/4885GAA 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.